Sector News

Envision Healthcare to pick up Imaging Advantage

March 8, 2017
Life sciences

Envision Healthcare has inked a deal to acquire Imaging Advantage, a move that will boost its presence in radiology physician services. Financial details were not disclosed.

Formed by AmSurg and Envision’s merger last December, the acquirer provides physician-led services, ambulatory surgery services, post-acute care and medical transportation. Imaging Advantage offers a cloud-based platform connecting more than 500 radiologists across 450 health facilities in 26 states. The transaction is expected to close in the second quarter.

“We believe the merger with Envision creates a valuable, integrated platform for radiologists and leverages our innovative radiology care model,” said Imaging Advantage CEO Naseer Hashim in a statement. “ … The merger will enable us to more effectively preserve and advance the intrinsic and important role of providers in their local communities, while managing relationships with health systems and enhancing service levels for referring physicians.”

“What [Imaging Advantage] does is similar to the business models of Amazon, Airbnb and Uber. We deploy innovative algorithms to match supply and demand in the cloud to turn … waste into value,” Hashim said in a 2015 Forbes interview.

Connecting radiologists and hospitals in its cloud platform gives each facility access to hundreds of physicians, rather than the few each has onsite. This can cut image turnaround times and, in turn, reduce wait times in emergency rooms and a patient’s hospital stay, he said.

In December 2015, Imaging Advantage partnered with RadNet, which operates outpatient radiology centers, to bring cloud-based radiology services to centers across the country.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach